Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue (2016 - 2025)

Wave Life Sciences' Current Deferred Revenue history spans 10 years, with the latest figure at $44.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 32.64% year-over-year to $44.4 million; the TTM value through Dec 2025 reached $44.4 million, down 32.64%, while the annual FY2025 figure was $44.4 million, 32.64% down from the prior year.
  • Current Deferred Revenue reached $44.4 million in Q4 2025 per WVE's latest filing, down from $46.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $150.1 million in Q4 2023 to a low of $8.7 million in Q3 2021.
  • Average Current Deferred Revenue over 5 years is $67.4 million, with a median of $49.1 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: crashed 89.86% in 2021, then skyrocketed 375.5% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $37.1 million in 2021, then fell by 14.93% to $31.6 million in 2022, then surged by 375.5% to $150.1 million in 2023, then crashed by 56.04% to $66.0 million in 2024, then crashed by 32.64% to $44.4 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Current Deferred Revenue are $44.4 million (Q4 2025), $46.5 million (Q3 2025), and $51.6 million (Q2 2025).